- Branża: Government; Health care
- Number of terms: 6957
- Number of blossaries: 0
- Company Profile:
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for ...
A radioconjugate containing the nucleoside analog 2'-fluoro-2'-deoxy-1beta-D-arabinofuranosyl-5-iodouracil (FIAU) labeled with the radioisotope iodine I 124 with positron-emitting activity. Chemotherapeutic agents such as bortezomib may induce viral thymidine kinase expression in EBV- and Kaposi's sarcoma herpesvirus (KSHV)-associated tumors. Subsequent to chemotherapy induction of viral TK in these tumors, administered iodine I 124 FIAU is phosphorylated by expressed viral TK, becoming selectively trapped within TK-expressing tumor cells; these cells can then be visualized with positron emission tomography (PET). Viral TK is either not expressed or is expressed at very low levels in EBV- and Kaposi's sarcoma herpesvirus (KSHV)-associated tumors and may be activated by certain chemotherapeutic agents.
Industry:Pharmaceutical
A radioconjugate containing the galactose analogue 2-deoxy-2-fluoro-D-glucose (FDGal) that contains the positron-emitting radioactive isotope fluorine F18, used for imaging upon positron emitting tomography (PET). With cell uptake much higher in tumor cells compared to normal cells, the F18 moiety of fluorodeoxygalactose F-18 can be visualized upon PET imaging and this agent can be used as a tracer for the evaluation of galactose tumor uptake and metabolism.
Industry:Pharmaceutical
A radioconjugate containing hydroxydiphosphonate (HDP) labeled with the metastable radioisotope technetium Tc (99mTc), with radioimaging activity. Upon intravenous administration, skeletal uptake of technetium Tc-99m HDP occurs as a function of skeletal blood flow and osteogenic activity. HDP has a specific affinity for hydroxyapatite crystals in bone where abnormal accumulation of increased osteoid mineralization has occurred. Labeling of HDP with 99mTc allows gamma scintigraphic imaging of areas of abnormal osteogenesis associated with malignant bone lesions.
Industry:Pharmaceutical
A radioconjugate containing the acetate salt of eribulin, labeled with the beta particle-emitting radioisotope carbon C 14 , with radioisotopic and potential antineoplastic activities. Upon administration, eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression. The radioisotope moiety of this agent acts as a radioactive tracer.
Industry:Pharmaceutical
A radioconjugate consisting of the somatostatin analog octreotate labeled with lutetium Lu 177 with receptor ligand, beta-emitting radioisotope, and potential antineoplastic activities. Lutetium Lu 177-DOTA-octreotate binds to somatostatin receptors (SSTRs), especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Lutetium Lu 177-DOTA-octreotate is produced by substituting the natural amino acid Thr for the alcohol Thr(ol) at the C terminus of the somatostatin analog octreotide and chelating the octreotate to Lu 177 via dodecanetetraacetic acid (DOTA).
Industry:Pharmaceutical
A radioconjugate consisting of the positron emitting radioisotope fluorine F 18 conjugated to the substance P antagonist receptor quantifier (SPA-RQ) used in radioimaging. (18F)-labeled substance P antagonist receptor quantifier is an antagonist of the neurokinin 1 (substance P) receptor (NK1R) and can function as a positron emission tomography (PET) imaging agent for detecting NK1R-expressing cells and tissues. NK1Rs are frequently expressed on the plasma membranes of tumor cells from glioblastoma and breast and pancreatic carcinomas.
Industry:Pharmaceutical
A radioconjugate consisting of the octreotide derivative edotreotide (Tyr3-octreotide or TOC) labeled with lutetium Lu 177 with receptor ligand, beta-emitting radioisotope, and potential antineoplastic activities. Similar to the somatostatin analog octreotide, lutetium Lu 177-edotreotide binds to somatostatin receptors (SSTRs), especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Lutetium Lu 177-edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide and chelating the substituted octreotide to Lu 177 via dodecanetetraacetic acid (DOTA).
Industry:Pharmaceutical
A radioconjugate consisting of the benzamide ligand ISO-1 labeled with the radioisotope fluorine F18 with positron-emitting radioisotope activity. Upon administration, fluorine (F18)ISO-1 binds to sigma-2 receptors, located on tumor cells, allowing visualization of sigma-2 receptor-expressing tumor cells with positron emission tomography (PET). Sigma-2 receptors, expressed in a variety of normal healthy tissues such as liver, kidneys, endocrine glands, and in the central nervous system, may be overexpressed in tumor cells.
Industry:Pharmaceutical
A radioconjugate consisting of sestamibi labeled with the positron-emitting isotope Tc 94m. Sestamibi is a synthetic molecule of the isonitrile family that diffuses through cell membranes and may preferentially accumulate within mitochondria. Technetium Tc 94m sestamibi may be used in tumor-imaging studies utilizing positron emission tomography (PET).
Industry:Pharmaceutical
A radioconjugate consisting of dextromethorphan, a synthetic, methylated dextrorotatory analogue of levorphanol, conjugated with carbon-13 ((13)C) with radiotracer activity. (13)C-dextromethorphan can be used in a breath-test phenotype assay of CYP2D6 activity, based on the principle that CYP2D6-mediated O-demethylation cleaves a (13)CH3 that enters the body's carbon pool to be eliminated ultimately as (13)CO2 in expired air, which can be measured. The (13)C-dextromethorphan breath test may prove useful in identifying poor CYP2D6 metabolizers of such important clinical drugs as tamoxifen.
Industry:Pharmaceutical
